2 to 65 Year Olds With Tuberous Sclerosis Complex (TSC) and Facial Angiofibromas Needed for Research Study
What is the purpose of this study?
Cincinnati
Children’s is conducting a research study, sometimes known as a clinical trial
or clinical study, to determine if the appearance of facial angiofibromas, or
elevated skin lesions, is reduced when a cream containing the investigational
medication Rapamycin is rubbed onto them.
The study will also
make sure Rapamycin is safe to use in people diagnosed with Tuberous Sclerosis
Complex (TSC).
Who can participate?
Children, teens and
adults 2 to 65 years old who have visible angiofibromas and are diagnosed with
TSC may be eligible to participate.
Participants
must not be on any Mammalian Target of Rapamycin (mTOR) inhibitors
prior to being in this study. Examples of mTOR inhibitors are rapamycin,
afinitor, sirolimus, everolimus and rapamune.
What is involved?
You
or your child will be in the research study for about 7 months and have 7 study
visits.
You
or your child will be randomly selected to join 1 of 3 different study
groups. One group will receive a low
dose of the study drug, another group will receive a higher dose of the study
drug and the third group will receive a cream that contains no medication. Neither you nor the study doctor will know
what group you or your child will be in.
The following is a list of some of the procedures that will take place
during the study:
- Medical and medication history
- Physical exam
- Photographs of the
angiofibromas
- Quality of Life Questionnaire
- Blood draw
What are the benefits?
You
or your child might not receive a direct medical benefit. However, the information gained from this
study may help other people with TSC in the future.
Will I get all the facts about the study?
As someone interested in
participating or as a parent interested in having your child participate, you
will be given a consent form that thoroughly explains all of the details of the
study. The form covers all of the procedures, the risks, the benefits, the pay,
who to contact with questions or concerns and more. A member of the study staff
will review the consent form with you and will be sure that all of your
questions are answered. Study procedures will not begin until a parent or
guardian has signed this form.
Do participants receive pay, compensation or reimbursement?
Participants will
not be compensated but will receive the study medication at no cost.
Who should I contact for more information?
Nikki
Kamos
513-636-9669
nichole.kamos@cchmc.org
Tuberous Sclerosis Clinic
Cincinnati
Children’s Hospital Medical Center
3333
Burnet Ave.
Cincinnati,
OH 45229-3039
Principal Investigator
Darcy
Krueger, MD, PhD
Tuberous Sclerosis Clinic
Department of Neurology
Cincinnati
Children’s Hospital Medical Center
3333
Burnet Ave.
Cincinnati,
OH 45229-3039